New hope for Sun-Sensitive patients: bitopertin Long-Term trial launches
NCT ID NCT05883748
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 29 times
Summary
This study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain when skin is exposed to sunlight. The drug bitopertin is being tested to see if it can safely increase the time patients can spend in daylight without pain. About 230 participants who have already been in a bitopertin study will take the drug long-term, and researchers will monitor side effects and changes in blood markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
Einstein Medical Center
Philadelphia, Pennsylvania, 19141, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
MetroBoston Clinical Partners
Boston, Massachusetts, 02135, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Remington-Davis Clinical Research
Columbus, Ohio, 43215, United States
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
University of Alabama Hospital
Birmingham, Alabama, 35233, United States
-
University of California San Francisco
San Francisco, California, 94117, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
-
University of Texas
Galveston, Texas, 77550, United States
Conditions
Explore the condition pages connected to this study.